pharmaphorum4mon
Roche launches 'revolutionary' pathogen detection tech
The new test is compatible with Roche's cobas 5800, 6800, and 8800 molecular diagnostic analysers ... of SARS-CoV-2 assays on the cobas 6800/8800 systems since the end of the pandemic.
Hosted on MSN21d
Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver
Roche Diagnostics CEO Matt Sause said: “Rapid molecular point-of-care testing ... CE mark certification for its updated cobas 6800/8800 systems 2.0, enhancing laboratory and testing capabilities.
pharmaphorum1d
Roche sticks with molecular glue, partnering Monte Rosa
Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...
Yahoo Finance22d
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
Basel, 22 January 2025 - Roche (SIX: RO, ROG ... with commercialisation under CE mark expected to follow shortly. “Rapid molecular point-of-care testing can revolutionise the clinical management ...
Pharm Exec23d
FDA Grants 510(k) Clearance to Roche’s Cobas Liat Molecular Test for Sexually Transmitted Infections
The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based settings for patients at risk for chlamydia, gonorrhea, and Mycoplasma ...
PharmiWeb23d
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
said Matt Sause, CEO Roche Diagnostics. The cobas liat system utilises gold-standard PCR technology to provide results in 20 minutes or less. The cobas liat assays are CLIA waived*, enabling ...